{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:44:06Z","timestamp":1792079046785,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.modpat.2026.101078","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:50:42Z","timestamp":1787925042000},"page":"101078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Albumin In Situ Hybridization in Genetically Characterized Cholangiocarcinoma and Tumors of Other Origins"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7260-6480","authenticated-orcid":false,"given":"Jay","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte I.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda T.","family":"Nieman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Desphande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.modpat.2026.101078_bib1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101078_bib2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ajpath.2024.10.013","article-title":"Genetic, epigenetic, and microenvironmental drivers of cholangiocarcinoma","volume":"195","author":"Putatunda","year":"2025","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101078_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep"},{"issue":"3","key":"10.1016\/j.modpat.2026.101078_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.modpat.2026.101078_bib5","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41416-022-01932-1","article-title":"Precision oncology for intrahepatic cholangiocarcinoma in clinical practice","volume":"127","author":"Tomczak","year":"2022","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2026.101078_bib6","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.modpat.2026.101078_bib7","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101078_bib8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.modpat.2026.101078_bib9","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.modpat.2026.101078_bib10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101078_bib11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.modpat.2026.101078_bib12","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/2159-8290.CD-20-1669","article-title":"FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma","volume":"11","author":"Cleary","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.modpat.2026.101078_bib13","article-title":"Molecular modeling and functional analysis of exome sequencing-derived variants of unknown significance identify a novel, constitutively active FGFR2 mutant in cholangiocarcinoma","volume":"2017","author":"Egan","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101078_bib14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101078_bib15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1245\/s10434-014-4247-8","article-title":"The ability to diagnose intrahepatic cholangiocarcinoma definitively using novel branched DNA-enhanced albumin RNA in situ hybridization technology","volume":"23","author":"Ferrone","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101078_bib16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ajcp\/aqz032","article-title":"Albumin in situ hybridization can be positive in adenocarcinomas and other tumors from diverse sites","volume":"152","author":"Nasir","year":"2019","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101078_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/PAI.0000000000000882","article-title":"A subset of intrahepatic cholangiocarcinomas express albumin RNA as detected by in situ hybridization","volume":"29","author":"Avadhani","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101078_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/jcp-2024-209429","article-title":"Combined analysis of albumin in situ hybridisation and C reactive protein immunohistochemistry for the diagnosis of intrahepatic cholangiocarcinoma: towards a molecular classification paradigm","volume":"78","author":"Albrecht","year":"2025","journal-title":"J Clin Pathol"},{"issue":"6","key":"10.1016\/j.modpat.2026.101078_bib19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.modpat.2026.101078_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.modpat.2026.101078_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.modpat.2026.101078_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.modpat.2026.101078_bib23","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.modpat.2026.101078_bib24","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.modpat.2026.101078_bib25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"269","key":"10.1016\/j.modpat.2026.101078_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"23","key":"10.1016\/j.modpat.2026.101078_bib27","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.modpat.2026.101078_bib28","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/PAS.0000000000001118","article-title":"Intrahepatic cholangiocarcinomas have histologically and immunophenotypically distinct small and large duct patterns","volume":"42","author":"Sigel","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101078_bib29","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.26131","article-title":"Preexisting epithelial diversity in normal human livers: a tissue-tethered cytometric analysis in portal\/periportal epithelial cells","volume":"57","author":"Isse","year":"2013","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.modpat.2026.101078_bib30","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.modpat.2026.101078_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118273","article-title":"Synergistic suppression of cholangiocarcinoma cells via DNA damage response and cell cycle arrest by dual targeting PARP and ATM in DNA damage repair pathway","volume":"189","author":"Jaidee","year":"2025","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.modpat.2026.101078_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-24420-x","article-title":"Establishment of novel cholangiocarcinoma cell lines with ARID1A deficiency and preclinical validation of synthetic lethality therapies","volume":"15","author":"Prasopporn","year":"2025","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.modpat.2026.101078_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcmgh.2025.101720","article-title":"Pbrm1 loss induces a permissive chromatin state for cholangiocytic differentiation and cholangiocarcinoma formation","volume":"20","author":"Chiou","year":"2026","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.modpat.2026.101078_bib34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/15384101.2020.1729450","article-title":"A novel EZH2 inhibitor induces synthetic lethality and apoptosis in PBRM1-deficient cancer cells","volume":"19","author":"Huang","year":"2020","journal-title":"Cell Cycle"},{"key":"10.1016\/j.modpat.2026.101078_bib35","article-title":"Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway-deficient neoplasms","volume":"8","author":"George","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.modpat.2026.101078_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.567289","article-title":"Case report: BAP1 mutation and RAD21 amplification as predictive biomarkers to PARP inhibitor in metastatic intrahepatic cholangiocarcinoma","volume":"10","author":"Sabbatino","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101078_bib37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41698-025-01113-2","article-title":"Prolonged survival in a patient with pbrm1 mutated metastatic cholangiocarcinoma receiving tazemetostat","volume":"9","author":"Pedregal","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101078_bib38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cjp2.103","article-title":"Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers","volume":"4","author":"Khalique","year":"2018","journal-title":"J Pathol Clin Res"},{"issue":"8","key":"10.1016\/j.modpat.2026.101078_bib39","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod Pathol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:46:07Z","timestamp":1792075567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226001213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0893395226001213"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101078","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Albumin In Situ Hybridization in Genetically Characterized Cholangiocarcinoma and Tumors of Other Origins","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"101078"}}